<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02740179</url>
  </required_header>
  <id_info>
    <org_study_id>2016P000464</org_study_id>
    <nct_id>NCT02740179</nct_id>
  </id_info>
  <brief_title>Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)</brief_title>
  <official_title>Mineralocorticoid Receptor Antagonism for Cardiovascular Health in HIV--The MIRACLE HIV Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV-infected individuals treated with antiretroviral medications are living longer, but have
      an increased risk of heart disease when compared to non-HIV-infected individuals. A hormone
      called aldosterone, which regulates blood pressure and sodium balance, is elevated in the HIV
      population in association with with increased belly fat and altered glucose metabolism.
      Elevations in aldosterone hormone may also be associated with abnormal blood flow,
      inflammation, and coronary plaque in the heart. This study is being conducted to evaluate
      whether therapies to reduce the actions of aldosterone may decrease the burden and
      progression of heart disease in the HIV population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 12 month randomized, placebo controlled study enrolling HIV-infected individuals
      with no known history of cardiovascular disease. Eplerenone is a mineralocorticoid receptor
      antagonist, which can block aldosterone activation. This medication is approved by the FDA
      for high blood pressure and heart failure. This study aims to investigate the effect of
      eplerenone on other measures of cardiovascular disease in HIV. Using PET, MRI, and CT imaging
      technology, this study will evaluate whether eplerenone can improve coronary flow reserve and
      myocardial inflammation/fibrosis, in addition to atherosclerotic plaque build-up among the
      HIV population. The study also includes teaching on lifestyle modification to promote a
      healthy diet and exercise program.There are 3 overnight visits in addition to safety visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary Flow Reserve</measure>
    <time_frame>12 Months</time_frame>
    <description>Coronary Flow Reserve measured via Cardiac Positron Emission Tomography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial Inflammation</measure>
    <time_frame>12 Months</time_frame>
    <description>Myocardial Inflammation measured by extracellular volume fraction via Cardiac Magnetic Resonance Imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coronary Plaque</measure>
    <time_frame>12 Months</time_frame>
    <description>Coronary Plaque measured via Coronary Computed Tomography Angiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Vascular Dysfunction</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Systemic Inflammation</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Immune Activation</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Subclinical Injury</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Fibrosis</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Inflammation</measure>
    <time_frame>12 Months</time_frame>
    <description>Arterial Inflammation measured via Aortic Positron Emission Tomography/Computed Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Arterial Inflammation</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplerenone 50 mg daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>Eplerenone 50mg by mouth daily</description>
    <arm_group_label>Eplerenone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo by mouth daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle Modification</intervention_name>
    <description>Counseling regarding diet and healthy activity</description>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages 40-65 years

          2. Antiretroviral use (ART) &gt;12 months and HIV viral load &lt;100 copies/mL

          3. VAT&gt; 110cm2

        Exclusion Criteria:

          1. Antihypertensive use including, ACE Inhibitor, ARB, MR blockade, diuretic, potassium
             (K) supplementation; or BP&gt;140/90 mmHg. Stable use (&gt;3 months) of beta-blockers or
             calcium channel blockers (CCB) (except verapamil) is allowed.

          2. Statin use in the past 3 months.

          3. Use of full dose ritonavir, nelfinavir, clarithromycin, and other strong inhibitiors
             of CYP3A4, as well as CYP3A4 inducers.

          4. Continuous oral steroid use (equivalent to prednisone &gt; 5 mg daily) within the last 3
             months.

          5. Uncontrolled diabetes requiring insulin and/or HbA1c &gt; 7.5%.

          6. Creatinine (Cr) &gt; 1.5 mg/dL or estimated GFR&lt;60 mL/min/1.73m2.

          7. K &gt; 5.5 mEq/L.

          8. Hemoglobin &lt; 10 g/dL.

          9. Known liver disease or ALT &gt;3x ULN.

         10. History of congestive heart failure, stroke, myocardial infarction, or known coronary
             artery disease.

         11. Pregnant, actively seeking pregnancy or breastfeeding.

         12. Estrogen, progestin derivative, or other sex steroid use within last 3 months. Stable
             physiologic testosterone replacement (&gt; 3 months) is acceptable.

         13. Current bacterial or other infections.

         14. Active substance abuse.

         15. Significant radiation exposure over the course of the year prior to randomization
             (e.g., radiation therapy, PCI, catheter ablation of arrhythmia) within 12 months of
             randomization.

         16. Previous reaction or contraindication to iodine-containing contrast media and
             gadolinium.

         17. Coronary artery luminal narrowing &gt;70% on coronary CTA.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Suman Srinivasa, MD, MS</last_name>
    <phone>6177269109</phone>
    <email>ssrinivasa@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steven K. Grinspoon, MD</last_name>
    <phone>6177269109</phone>
    <email>sgrinspoon@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suman Srinivasa, MD, MS</last_name>
      <phone>617-724-9109</phone>
      <email>ssrinivasa@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Steven K. Grinspoon, MD</last_name>
      <phone>6177249109</phone>
      <email>sgrinspoon@mgh.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Srinivasa S, Fitch KV, Wong K, Torriani M, Mayhew C, Stanley T, Lo J, Adler GK, Grinspoon SK. RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients. J Clin Endocrinol Metab. 2015 Aug;100(8):2873-82. doi: 10.1210/jc.2015-1461. Epub 2015 Jun 18.</citation>
    <PMID>26086328</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven K. Grinspoon, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Eplerenone</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Mineralocorticoid Receptor Antagonist</keyword>
  <keyword>Coronary Vasculature</keyword>
  <keyword>Myocardial Inflammation</keyword>
  <keyword>Myocardial Fibrosis</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Aldosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
    <mesh_term>Mineralocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

